Aitia
So-Youn Shin's work experience includes various roles in the field of research and scientific leadership. So-Youn started their career as a Postdoctoral Research Fellow at the Wellcome Trust Sanger Institute in 2009 and worked there until 2012. After that, they joined the University of Bristol as an Oak Foundation Research Fellow for four years. In 2016, they moved to Aitia and began their journey there as a Senior Scientist. Over the years, they progressed through different positions, including Principal Scientist, Associate Director, Director, and currently holds the position of Senior Director since 2023.
So-Youn Shin completed their Ph.D. in Statistics from Stony Brook University Graduate School in 2009. Prior to this, they attended Seoul National University, although specific details about their degree or field of study at that institution are not provided.
This person is not in any teams
This person is not in any offices
Aitia
1 followers
Aitia is the leader in the application of Causal AI and Digital Twins to discover the next generation of breakthrough drugs. By leveraging the convergence of multi-omic patient data, high-performance computing, and causal learning and AI, Aitia is revealing the hidden biological mechanisms of disease to create Digital Twins of disease in oncology,neurodegenerative disorders, and immunology. Gemini Digital Twins are being used today to discover novel therapies and accelerate R&D in multiple myeloma, prostate cancer, Alzheimer’s Disease, Parkinson’s Disease, and Huntington’s Disease, with several more in development. Aitia’s partners include seven of the top ten pharmaceutical companies, leading academic research and medical centers, medical societies, leading multi-omic data companies, and patient advocacy groups globally.